Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy.
about
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesA comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabRheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis.A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis.An evidence-based review of skin cancer rates on biologic therapies.A practical approach to monitoring patients on biological agents for the treatment of psoriasisEtanercept in the treatment of plaque psoriasisSolid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.Soluble cytokine receptors in biological therapy.Cytokine and anticytokine therapy in dermatology.Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies.Roles of the immune system in skin cancer.The safety of etanercept for the treatment of plaque psoriasis.Treatment of inflammatory dermatoses by tumour necrosis factor antagonists.Interaction between comorbidity and cancer.Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)?Combining systemic retinoids with biologic agents for moderate to severe psoriasis.TNF-α inhibitors: are they carcinogenic?Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature.TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis.Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.Amelioration of human osteoarthritis symptoms with topical 'biotherapeutics': a phase I human trial.Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.Biologics in dermatology: adverse effects.Etanercept-induced lichenoid reaction pattern in psoriasis.The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.Infliximab therapy for sarcoidosis (lupus pernio).Unusual and Interesting Adverse Cutaneous Drug Reactions.Neoplasms
P2860
Q24806367-924FC709-32D6-4DDF-A1AB-6A9AD36252D3Q28282330-ACC2CB5E-02E0-4BE3-8718-5EC16D94D77AQ31041008-061E8F05-70E1-446F-80D2-46B954F1BE1EQ33530087-620A1230-2D2B-4410-B89B-1623101404CDQ33904746-4E712B13-FD4F-49EC-84DB-3EE9AD88D1B8Q34107637-FB475799-B952-48BA-AFF1-D4F38B32216CQ34156420-0B1E2699-1989-4C68-894F-BCE1ECE771D2Q34620263-4B686A00-4BA0-46B6-89B8-48D6CE1A35A9Q34628409-7482070A-B3F9-4FB5-928E-407E07EBB690Q34779777-E1D1DE08-88BD-47AC-BAB1-EC9461AF0F29Q35184711-80E2BBD4-BB73-40FF-8B0E-5B350B3E42A9Q35208404-4AFD42D7-387C-4ABB-AFFA-7F12871F622EQ35403714-9A70960B-5156-42F3-82A3-243B51C8829AQ35919214-5987C5BE-918C-4EC3-9842-91D7639AB40AQ36633460-B2D23AF8-733A-4A91-98BB-39277A5F14DAQ36715254-1A92F68E-A5DE-4066-8069-08E6FF89FBF7Q36738727-DC3E738F-96D2-40EE-A729-4FF9828FE8C0Q36983518-7D6C2D35-8CF2-4C28-9DC1-C6DA82E7E75CQ37138608-0C8C7E16-EA23-4A8B-8B77-A515555537BCQ37893973-6E68C886-C359-45FB-A74B-01F1BA565AABQ37957993-548D3998-813E-4A7B-B9AC-0335C29F449EQ38041477-404467C2-523B-484B-BD22-C0E0ED2C7BE5Q38099248-7F69DE77-44F2-4074-80D2-72B712AB469EQ38271768-FDEB2A19-5F24-459D-A6C4-D0EC6E1E3111Q38663608-47192A6F-B42B-43F4-AC30-5236EF5C33E1Q41120913-8641F5C1-706B-4025-AC83-1A717D340547Q42518741-C5D23D76-309C-4E1F-B2B0-B1249FAC2667Q42635096-111CC1C3-2F33-48C8-9951-14312F6624CBQ43625754-20695F8C-A41E-4E90-82F1-91042C3A6F4BQ44744561-F2182D80-4CE9-4A6A-8FEB-1C0B5B893A42Q55099672-436B86A3-CC1F-44A0-BCC9-371C123E9EC2Q56828372-89BE87E4-998F-4FD6-B251-5AE40077A1BF
P2860
Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@ast
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@en
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@nl
type
label
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@ast
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@en
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@nl
prefLabel
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@ast
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@en
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@nl
P356
P1476
Rapid onset of cutaneous squam ...... gG1-Fc fusion complex therapy.
@en
P2093
P304
P356
10.1067/MJD.2001.117725
P407
P577
2001-12-01T00:00:00Z